On the other hand, there were studies reported the activity of second-generation EGFR-TKI afatinib in treating uncommon EGFR mutations, which encourage the exploration of other second-generation EGFR-TKIs in treating advanced NSCLC harboring uncommon EGFR mutations [10]. Here, EGFR is linked to non-small cell lung carcinoma.